BCL2 and lymphoma: We do not believe that an inherent feature of Eμ-Myc lymphomas make them particularly sensitive to the effects of elongation inhibitor/Dxr combination since Eμ-Myc/Bcl-2 lymphomas showed significant resistance to these drug combinations (Fig. 2B).